image
Healthcare - Drug Manufacturers - General - NYSE - CH
$ 97.53
-0.337 %
$ 191 B
Market Cap
17.02
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NVS stock under the worst case scenario is HIDDEN Compared to the current market price of 97.5 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NVS stock under the base case scenario is HIDDEN Compared to the current market price of 97.5 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NVS stock under the best case scenario is HIDDEN Compared to the current market price of 97.5 USD, Novartis AG is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
46.7 B REVENUE
-9.97%
9.77 B OPERATING INCOME
6.22%
8.57 B NET INCOME
23.25%
14.5 B OPERATING CASH FLOW
1.56%
5.6 B INVESTING CASH FLOW
281.20%
-14.3 B FINANCING CASH FLOW
30.56%
13.2 B REVENUE
5.27%
3.63 B OPERATING INCOME
-7.66%
3.19 B NET INCOME
-1.76%
6.29 B OPERATING CASH FLOW
28.94%
-374 M INVESTING CASH FLOW
88.34%
-382 M FINANCING CASH FLOW
88.06%
Balance Sheet Novartis AG
image
Current Assets 30.5 B
Cash & Short-Term Investments 14 B
Receivables 8.12 B
Other Current Assets 8.4 B
Non-Current Assets 69.5 B
Long-Term Investments 1.83 B
PP&E 10.9 B
Other Non-Current Assets 56.7 B
Current Liabilities 26.4 B
Accounts Payable 4.93 B
Short-Term Debt 6.31 B
Other Current Liabilities 15.2 B
Non-Current Liabilities 26.8 B
Long-Term Debt 20 B
Other Non-Current Liabilities 6.77 B
EFFICIENCY
Earnings Waterfall Novartis AG
image
Revenue 46.7 B
Cost Of Revenue 12.5 B
Gross Profit 34.2 B
Operating Expenses 24.4 B
Operating Income 9.77 B
Other Expenses 1.2 B
Net Income 8.57 B
RATIOS
73.27% GROSS MARGIN
73.27%
20.94% OPERATING MARGIN
20.94%
31.83% NET MARGIN
31.83%
31.82% ROE
31.82%
14.86% ROA
14.86%
12.89% ROIC
12.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novartis AG
image
Net Income 8.57 B
Depreciation & Amortization 8.28 B
Capital Expenditures -2.75 B
Stock-Based Compensation 865 M
Change in Working Capital -369 M
Others -2.24 B
Free Cash Flow 11.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novartis AG
image
Wall Street analysts predict an average 1-year price target for NVS of $117 , with forecasts ranging from a low of $108 to a high of $121 .
NVS Lowest Price Target Wall Street Target
108 USD 10.74%
NVS Average Price Target Wall Street Target
117 USD 19.71%
NVS Highest Price Target Wall Street Target
121 USD 24.06%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
3.78 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Novartis AG
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Why Novartis (NVS) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 1 week ago
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal. zacks.com - 2 weeks ago
Here's Why Novartis (NVS) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2 weeks ago
Novartis gene therapy helps children with rare muscle disorder in study Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow. reuters.com - 2 weeks ago
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profile Novartis plans to share results with regulatory agencies in 2025 with the aim to make OAV101 IT available to help patients with SMA in need Basel, [December 30, 2024] – Novartis today announced positive topline results from the Phase III STEER study. globenewswire.com - 2 weeks ago
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya. reuters.com - 3 weeks ago
Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term These five laggards of this year have double-digit upside left in the near term. They are: UBER, NVS, RYAAY, OKTA, BAH. zacks.com - 3 weeks ago
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected. reuters.com - 1 month ago
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging globenewswire.com - 1 month ago
NVS vs. LLY: Which Stock Should Value Investors Buy Now? Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors? zacks.com - 1 month ago
Are Investors Undervaluing Novartis (NVS) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Novartis: Time To Increase Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus. seekingalpha.com - 1 month ago
8. Profile Summary

Novartis AG NVS

image
COUNTRY CH
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 191 B
Dividend Yield 0.00%
Description Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Contact Lichtstrasse 35, Basel, 4056 https://www.novartis.com
IPO Date Nov. 7, 1996
Employees 76057
Officers Mr. Victor Bulto President of US Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer Paul Penepent Head of Group Financial Reporting and Accounting Ms. Karen L. Hale Chief Legal Officer Dr. Vasant Narasimhan M.D. Chief Executive Officer Dr. Steffen Lang Ph.D. President of Operations Mr. Harry Kirsch Chief Financial Officer Dr. Patrick Horber M.D. President of International Ms. Sloan Simpson Global Head of Investor Relations Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer